Appropriatezza diagnostico-terapeutica in oncologia - Quaderni del ...

Linfomi 7
Tumours of Haematopoietic and Lymphoid Tissues.
3 rd Edition. Lyon: IARC Press, 2001
Ladetto M, De Marco F, Benedetti F, et al.; Gruppo
Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo
Italiano linfomi (IIL). Prospective, multi
center randomized GITMO/IIL trial comparing intensive
(R-HDS) versus conventional (CHOP-R) chemoimmunotherapy
in high-risk follicular lymphoma
at diagnosis: the superior disease control of R-HDS
does not translate into an overall survival advantage.
Blood 2008; 111: 4004-13
Lister TA, Crowther SB, Sutcliffe SB, et al. Report of
a committee convened to discuss the evaluation and
staging of patients with Hodgkin’s disease. Cotswolds
meeting. J Clin Oncol 1989; 7: 1630-6
Martelli M, Ferreri AJ, Johnson P. Primary mediastinal
large B-cell lymphoma. Crit Rev Oncol Hematol 2008;
68: 256-63
McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab
chimeric anti-CD20 monoclonal antibody therapy
for relapsed indolent lymphoma: half of patients respond
to a four-dose treatment program. J Clin Oncol 1998;
16: 2825-33
Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy
alone compared with chemotherapy plus radiotherapy
for localized intermediate- and high-grade non
Hodgkin’s lymphoma. N Engl J Med 1998; 339: 21-6
Morschhauser F, Radford J, Van Hoof A, et al. Phase
III trial of consolidation therapy with yttrium-90-
ibritumomab tiuxetan compared with non additional
therapy after first remission in advanced follicular lymphoma.
J Clin Oncol 2008; 26: 5156-64
Noordijk EM, Carde P, Dupouy N, et al. Combinedmodality
therapy for clinical stage I or II Hodgkin’s
lymphoma: long-term results of the European Organisation
for Research and Treatment of Cancer H7 randomized
controlled trials. J Clin Oncol 2006; 24:
3128-35
Paulli M, Artusi T, Baroni CD, et al. The Haemolymphopathology
Italian Group (HIG): an essential resource
for the new technic and organization problems
troubling modern haemolymphopathology diagnostics.
Patologica 2006; 98: 37-40
Peterson BA, Petroni GR, Frizzera G, et al. Prolonged
single-agent versus combination chemotherapy in indolent
follicular lymphomas: a study of the cancer
and leukemia group B. J Clin Oncol 2003; 21: 5-15
Pfreundschuh M, Schubert J, Ziepert M, et al.; German
High-Grade Non-Hodgkin Lymphoma Study
Group (DSHNHL). Six versus eight cycles of biweekly
CHOP-14 with or without rituximab in elderly
patients with aggressive CD20+ B-cell lymphomas: a
randomised controlled trial (RICOVER-60). Lancet
Oncol 2008; 9: 105-16
Pfreundschuh M, Trümper L, Osterborg A, et al.;
MabThera International Trial Group. CHOP-like
chemotherapy plus rituximab versus CHOP-like
chemotherapy alone in young patients with goodprognosis
diffuse large-B-cell lymphoma: a randomised
controlled trial by the MabThera International Trial
(MinT). Lancet Oncol 2006; 7: 379-91
Philip T, Guglielmi C, Hagenbeek A, et al. Autologous
bone marrow transplantation as compared with salvage
chemotherapy in relapses of chemotherapy-sensitive
non-Hodgkin’s lymphoma. N Engl J Med 1995; 333:
1540-45
Pileri SA, Sabattini E. Linee guida GIE. Trattamento
del campione bioptico. www.siapec.it. Ultima consultazione:
maggio 2010
Reimer P, Rüdiger T, Geissinger E, et al. Autologous
stem-cell transplantation as first-line therapy in peripheral
T-cell lymphomas: results of a prospective
multicenter study. J Clin Oncol 2009; 27: 106-13
Reyes F, Lepage E, Ganem G, et al. ACVBP versus
CHOP plus Radiotherapy for Localized Aggressive
Lymphom. N Engl J Med 2005; 352: 1197-205
Robinson Sureda A, Canals C, Russell N, et al.; Lymphoma
Working Party of the EBMT. Reduced intensity
conditioning allogeneic stem cell transplantation for
Hodgkin’s lymphoma: identification of prognostic fac-
147